Literature DB >> 28205314

Comparison of LC-MS/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective.

Zhipeng Wang1, Yunlei Yun1, Xinfang Xie1,2, Chunhua You1,2, Haijun Miao1, Feng Zhang1, Shouhong Gao1, Wansheng Chen1.   

Abstract

OBJECTIVES: This study was designed to compare the performance of LC-MS/MS with chemiluminescent microparticle immunoassay (CMIA) for determination of VPA in epilepsy patients in the perspective of metabolites' hepatotoxicity.
METHOD: Samples were collected and then analyzed using both LC-MS/MS and CMIA. A LO2 cells (normal human hepatic cells) experiment was carried out to confirm VPA metabolites' hepatotoxicity using AST(Aspertate Aminotransferase, AST), ALT(Alanine aminotransferase, ALT) and LDH(lactate dehydrogenase, LDH) in supernate as index.
RESULTS: The regression equation analysis showed as LC-MS/MS=1.0094CMIA-1.8937, with the concordance correlation coefficient of 0.9700, and the CUSUM test proved no significant deviation from linearity (P>.05). CMIA compared to LC-MS/MS gave a positive bias of 1.2 μg/mL. In LO2 experiment, VPA and its metabolites groups showed an obvious increment of AST, ALT, and LDH in supernate.
CONCLUSION: The LC-MS/MS is largely consistent with the CMIA in analytical time and quantification ability for VPA, but the LC-MS/MS can simultaneously determinate VPA and its metabolites in plasma, and is also a higher cost-efficiency method in consideration of toxic metabolites monitoring. The overestimation of VPA by CMIA showed no clinical significance. The metabolites 3-OH-VPA and 5-OH-VPA damage the LO2 cells and the results presented a statistical significance (P<.05). It is vital to monitor the metabolites' concentrations for VAP's clinical safety application, and now is the occasion that laboratory and clinic consider the LC-MS/MS method as a more advantageous alternative to CMIA method in therapeutic monitoring of VPA.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  LC-MS/MS; LO2 experiment; VPA and its metabolites; chemiluminescent microparticle immunoassay

Mesh:

Substances:

Year:  2017        PMID: 28205314      PMCID: PMC6817092          DOI: 10.1002/jcla.22157

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

1.  Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.

Authors:  Tony K L Kiang; Ping C Ho; M Reza Anari; Vincent Tong; Frank S Abbott; Thomas K H Chang
Journal:  Toxicol Sci       Date:  2006-08-31       Impact factor: 4.849

2.  [Relationship between plasma concentrations of valproic acid and hepatotoxicity in patients receiving high doses].

Authors:  H Ghozzi; A Hakim; Z Sahnoun; L Ben Mahmoud; R Atheymen; S Hammami; K Zeghal
Journal:  Rev Neurol (Paris)       Date:  2011-04-13       Impact factor: 2.607

Review 3.  Advances in anti-epileptic drug testing.

Authors:  Matthew D Krasowski; Gwendolyn A McMillin
Journal:  Clin Chim Acta       Date:  2014-06-10       Impact factor: 3.786

Review 4.  Valproate: past, present, and future.

Authors:  Cecilie U Johannessen; Svein I Johannessen
Journal:  CNS Drug Rev       Date:  2003

5.  The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.

Authors:  J W Kesterson; G R Granneman; J M Machinist
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

6.  Determination of valproic acid (di-N-propyl acetic acid) in plasma by gas-liquid chromatography with pre-column butylation.

Authors:  A Hulshoff; H Roseboom
Journal:  Clin Chim Acta       Date:  1979-04-02       Impact factor: 3.786

Review 7.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

8.  Development of water-phase derivatization followed by solid-phase microextraction and gas chromatography/mass spectrometry for fast determination of valproic acid in human plasma.

Authors:  Chunhui Deng; Ning Li; Jie Ji; Bei Yang; Gengli Duan; Xiangmin Zhang
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

9.  The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.

Authors:  Min Sun Lee; Young-Joo Lee; Bo Joon Kim; Kye Jung Shin; Bong Chul Chung; Du-Jong Baek; Byung Hwa Jung
Journal:  Arch Pharm Res       Date:  2009-07-31       Impact factor: 4.946

10.  In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.

Authors:  K Kassahun; F Abbott
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

View more
  3 in total

1.  Comparison of LC-MS/MS vs chemiluminescent microparticle immunoassay in measuring the valproic acid concentration in plasma of epilepsy patients in a new perspective.

Authors:  Zhipeng Wang; Yunlei Yun; Xinfang Xie; Chunhua You; Haijun Miao; Feng Zhang; Shouhong Gao; Wansheng Chen
Journal:  J Clin Lab Anal       Date:  2017-02-15       Impact factor: 2.352

2.  Simultaneous Quantification of Methotrexate and Its Metabolite 7-Hydroxy-Methotrexate in Human Plasma for Therapeutic Drug Monitoring.

Authors:  Xinxin Ren; Zhipeng Wang; Yunlei Yun; Guangyi Meng; Xialan Zhang; Huamin Ding; Ying Xu; Hansheng Bai; Jing Liu; Xia Li; Shouhong Gao; Lifeng Huang; Wansheng Chen
Journal:  Int J Anal Chem       Date:  2019-02-03       Impact factor: 1.885

Review 3.  New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs).

Authors:  Karina Sommerfeld-Klatta; Barbara Zielińska-Psuja; Marta Karaźniewcz-Łada; Franciszek K Główka
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.